SIGMA LABS INC (SGLB)

US8265985007 - Common Stock

1.05  +0.02 (+1.94%)

Fundamental Rating

3

SGLB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 65 industry peers in the Aerospace & Defense industry. The financial health of SGLB is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SGLB is valued expensive at the moment.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SGLB has reported negative net income.
In the past 5 years SGLB always reported negative net income.
In the past 5 years SGLB always reported negative operating cash flow.

1.2 Ratios

Industry RankSector Rank
ROA -76.17%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -750.81%
PM (TTM) -721.77%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, SGLB has more shares outstanding
There is no outstanding debt for SGLB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of 0.74, we must say that SGLB is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for SGLB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.74
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 11.66 indicates that SGLB has no problem at all paying its short term obligations.
A Quick Ratio of 10.79 indicates that SGLB has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 11.66
Quick Ratio 10.79

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.61% over the past year.
SGLB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.10%.
Measured over the past years, SGLB shows a quite strong growth in Revenue. The Revenue has been growing by 11.21% on average per year.
EPS 1Y (TTM)2.61%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-133.33%
Revenue 1Y (TTM)18.1%
Revenue growth 3Y61.74%
Revenue growth 5Y11.21%
Revenue growth Q2Q-89.13%

3.2 Future

SGLB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.92% yearly.
Based on estimates for the next years, SGLB will show a very strong growth in Revenue. The Revenue will grow by 43.01% on average per year.
EPS Next Y-32.39%
EPS Next 2Y-10.06%
EPS Next 3Y-1.5%
EPS Next 5Y1.92%
Revenue Next Year-52.74%
Revenue Next 2Y19.03%
Revenue Next 3Y34.08%
Revenue Next 5Y43.01%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SGLB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGLB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.19

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.06%
EPS Next 3Y-1.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGLB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SIGMA LABS INC

NASDAQ:SGLB (5/18/2022, 7:00:02 PM)

1.05

+0.02 (+1.94%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.03M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.17%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -750.81%
PM (TTM) -721.77%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 11.66
Quick Ratio 10.79
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)2.61%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-32.39%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)18.1%
Revenue growth 3Y61.74%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y